Two-Drug combo aims to outsmart resistant hodgkin lymphoma
Disease control
Terminated
This phase 2 study tests whether combining magrolimab and pembrolizumab can shrink or eliminate tumors in people with classic Hodgkin lymphoma that has come back or not responded to at least two prior treatments. Magrolimab targets a 'don't eat me' signal on cancer cells, while p…
Phase: PHASE2 • Sponsor: Ranjana Advani • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC